A recent phase 1 and 2 clinical study examining the effects of the pan-Trk inhibitor larotrectinib in children and adults with various types of peripheral solid cancers harboring NTRK gene fusions found pronounced and durable responses regardless of patient age or tumor type [147]. This evidence concerns the gene TPM3 and neoplasm.